ClinVar Miner

Submissions for variant NM_004360.5(CDH1):c.1370C>T (p.Thr457Met)

gnomAD frequency: 0.00001  dbSNP: rs587778170
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 11
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000219561 SCV000278251 uncertain significance Hereditary cancer-predisposing syndrome 2023-01-13 criteria provided, single submitter clinical testing The p.T457M variant (also known as c.1370C>T), located in coding exon 10 of the CDH1 gene, results from a C to T substitution at nucleotide position 1370. The threonine at codon 457 is replaced by methionine, an amino acid with similar properties. This variant was identified in a cohort of 681 ancestrally diverse, healthy subjects (Bodian DL et al. PLoS ONE, 2014 Apr;9:e94554). This alteration was also identified in 1/1358 non-cancer control individuals and in 0/57 cases, in a study looking at cancer predisposition mutations in patients with cutaneous melanoma and a history of at least two additional non-cutaneous melanoma primary cancers (Pritchard AL et al. PLoS One, 2018 May;13:e0194098). This amino acid position is poorly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Invitae RCV000229532 SCV000288431 uncertain significance Hereditary diffuse gastric adenocarcinoma 2023-11-22 criteria provided, single submitter clinical testing This sequence change replaces threonine, which is neutral and polar, with methionine, which is neutral and non-polar, at codon 457 of the CDH1 protein (p.Thr457Met). This variant is present in population databases (rs587778170, gnomAD 0.03%). This missense change has been observed in individual(s) with hereditary breast and ovarian cancer (PMID: 36436516). ClinVar contains an entry for this variant (Variation ID: 133845). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
GeneDx RCV000657011 SCV000617067 uncertain significance not provided 2023-09-11 criteria provided, single submitter clinical testing In silico analysis supports that this missense variant does not alter protein structure/function; Observed in individual(s) with family history of breast cancer (Garcia-Pelaez et al., 2023); This variant is associated with the following publications: (PMID: 24728327, 15235021, 22850631, 36436516, 29641532)
Color Diagnostics, LLC DBA Color Health RCV000219561 SCV000689451 uncertain significance Hereditary cancer-predisposing syndrome 2023-11-08 criteria provided, single submitter clinical testing This missense variant replaces threonine with methionine at codon 457 of the CDH1 protein. To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with CDH1-related disorders in the literature. This variant has been identified in 12/251482 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.
Counsyl RCV000229532 SCV000784772 uncertain significance Hereditary diffuse gastric adenocarcinoma 2017-10-03 criteria provided, single submitter clinical testing
Fulgent Genetics, Fulgent Genetics RCV000765305 SCV000896560 uncertain significance Familial cancer of breast; Blepharocheilodontic syndrome 1; Endometrial carcinoma; Hereditary diffuse gastric adenocarcinoma; Neoplasm of ovary; Malignant tumor of prostate 2018-10-31 criteria provided, single submitter clinical testing
European Reference Network on Genetic Tumour Risk Syndromes (ERN-GENTURIS), i3s - Instituto de Investigação e Inovação em Saúde, University of Porto RCV000229532 SCV003926784 uncertain significance Hereditary diffuse gastric adenocarcinoma 2022-08-01 criteria provided, single submitter clinical testing Not applicable criteria (PMID: 30311375)
Myriad Genetics, Inc. RCV000229532 SCV004020024 uncertain significance Hereditary diffuse gastric adenocarcinoma 2023-03-06 criteria provided, single submitter clinical testing This variant is classified as a variant of uncertain significance as there is insufficient evidence to determine its impact on protein function and/or cancer risk.
CeGaT Center for Human Genetics Tuebingen RCV000657011 SCV004033498 uncertain significance not provided 2023-08-01 criteria provided, single submitter clinical testing CDH1: PM2:Supporting, BP4
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000120497 SCV004241568 likely benign not specified 2023-12-21 criteria provided, single submitter clinical testing Variant summary: CDH1 c.1370C>T (p.Thr457Met) results in a non-conservative amino acid change located in the Cadherin-like domain (IPR002126) of the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 1.9e-05 in 1614058 control chromosomes, predominantly at a frequency of 0.00015 within the South Asian subpopulation in the gnomAD v4 database. The observed variant frequency within South Asian control individuals in the gnomAD database is approximately 7.2 fold of the estimated maximal expected allele frequency for a pathogenic variant in CDH1 causing Hereditary Breast And Ovarian Cancer Syndrome phenotype (2.1e-05), strongly suggesting that the variant is a benign polymorphism found primarily in populations of South Asian origin. c.1370C>T has been reported in the literature in at least one family affected with breast cancer (e.g., Garcia-Pelaez_2022), however without strong evidence for causality (e.g., lack of co-segregation data). This report therefore does not provide unequivocal conclusions about association of the variant with Hereditary Breast And Ovarian Cancer Syndrome. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publication was ascertained in the context of this evaluation (PMID: 36436516). Nine submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. All submitters classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as likely benign.
ITMI RCV000120497 SCV000084650 not provided not specified 2013-09-19 no assertion provided reference population

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.